Iovance Biotherapeutics reported early pilot trial results for lifileucel in aggressive soft tissue sarcomas. The company plans to start a registrational trial and seek expedited FDA approval based on ...

Synovial sarcoma, a rare cancer, thrives on glutamine. Blocking its nutrient supply with the drug V9302 stops tumor growth, offering a new way to treat the disease.

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, /CNW/ — Equity-Insider.com News Commentary — The five-year cancer survival rate in the United States has reached a record 70% ...

PARIS, FRANCE, 09 March 2026 ? Ipsen (Euronext: IPN; ADR: IPSEY) announced today that it is voluntarily withdrawing Tazverik® (tazemetostat) in all indications from all Ipsen markets. Ipsen's decision ...

Pazopanib produced responses and acceptable safety in paclitaxel-pretreated angiosarcoma; read more about outcomes and ...

Intensity Therapeutics, Inc. ("Intensity" or "the Company") (Nasdaq: INTS), a late-stage clinical biotechnology company ...

Results presented here showed negative pressure wound therapy is a safe adjunct for soft tissue sarcoma treated with ...

Long-term results from a phase 2 study presented at the 27th European Congress on Gynaecological Oncology (ESGO 2026) in Hong ...

A new cohort study suggests that Medicaid expansion is associated with a lower mortality risk among patients with pancreatic ...

CAR T-cell immunotherapy improved progression-free and overall survival in patients with relapsed or refractory marginal zone ...

A meta-analysis of 13 studies showed that patients who underwent sentinel node biopsy had a significantly reduced risk of death from melanoma. In addition, an analysis of nine studies showed that the ...

Screening detection is associated with increased survival rates even for stage IV breast cancer, according to a new study.